关键词: 瑞舒伐他汀, 沙库巴曲缬沙坦钠, 急性心肌梗死, 经皮冠状动脉介入治疗, 心功能, 血液流变学

Abstract:

Objective： To analyze the effects of combined rosuvastatin and sacubitril/valsartan therapy on cardiac function， hemorheology， and related outcomes in patients with acute myocardial infarction （AMI） undergoing percutaneous coronary intervention （PCI）.Methods： A retrospective analysis was performed on 143 AMI patients treated with PCI between March 2023 and February 2025. According to the treatment regimen， patients were divided into a control group （n=71， receiving rosuvastatin alone） and an observation group （n=72， receiving rosuvastatin combined with sacubitril/valsartan）. After 30 days of treatment， clinical efficacy， cardiac function parameters ［including left ventricular ejection fraction （LVEF）， left ventricular end-systolic diameter （LVESD）， left ventricular end-diastolic diameter （LVEDD）， and interventricular septal thickness （IVST）］， hemorheological indices ［including whole blood low-shear viscosity （WLV）， whole blood high-shear viscosity （WHV）， fibrinogen （FIB）， and D-dimer （D-D）］， myocardial enzyme levels ［creatine kinase-MB （CK-MB） and lactate dehydrogenase （LDH）］， 6-minute walking distance （6MWD）， and complication rates were compared between the two groups.Results： The observation group demonstrated a significantly higher total treatment response rate （91.67% vs. 78.87%， P<0.05） and a lower overall incidence of complications （15.28% vs. 29.58%， P<0.05） compared to the control group. After treatment， both groups showed increased LVEF， and 6MWD， while LVESD， LVEDD， IVST， WLV， WHV， FIB， D-D， LDH， and CK-MB were decreased compared to baseline （P<0.05）. Moreover， the magnitude of improvement in all the aforementioned indicators was significantly greater in the observation group than in the control group （P<0.05）.Conclusion： In patients with AMI undergoing PCI， the combination of rosuvastatin and sacubitril/valsartan can enhance short-term clinical efficacy， improve cardiac function， hemorheological status， and myocardial enzyme profiles， increase exercise tolerance， and reduce the risk of short-term complications.

Key words: Rosuvastatin； , Sacubitril/valsartan； , Acute myocardial infarction； , Percutaneous coronary intervention； , Cardiac function； , Hemorheology